NDC 0074-1043

Rinvoq

Upadacitinib

Rinvoq is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Upadacitinib.

• Product ID: 0074-1043_2ba2897f-6a03-40ad-8421-235895a25151
• NDC: 0074-1043
• Product Type: Human Prescription Drug
• Proprietary Name: Rinvoq
• Generic Name: Upadacitinib
• Dosage Form: Tablet, Extended Release
• Route of Administration: ORAL
• Marketing Start Date: 2019-08-16
• Marketing Category: NDA /
• Application Number: NDA211675
• Labeler Name: AbbVie Inc.
• Substance Name: UPADACITINIB
• Active Ingredient Strength: 45 mg/1
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0074-1043-14

14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-1043-14)

• Marketing Start Date: 2022-03-16
• NDC Exclude Flag: N
• Sample Package?: Y

Drug Details

NDC Crossover Matching brand name "Rinvoq" or generic name "Upadacitinib"

NDC	Brand Name	Generic Name
0074-1043	Rinvoq	Upadacitinib
0074-2306	Rinvoq	Upadacitinib
0074-2310	Rinvoq	Upadacitinib